Cargando…
Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?—Lessons Learned From Cancer
SARS-CoV-2 infection is a new threat to global public health in the 21(st) century (2020), which has now rapidly spread around the globe causing severe pneumonia often linked to Acute Respiratory Distress Syndrome (ARDS) and hyperinflammatory syndrome. SARS-CoV-2 is highly contagious through saliva...
Autores principales: | Barbieri, Antonio, Robinson, Nirmal, Palma, Giuseppe, Maurea, Nicola, Desiderio, Vincenzo, Botti, Gerardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561388/ https://www.ncbi.nlm.nih.gov/pubmed/33117402 http://dx.doi.org/10.3389/fimmu.2020.588724 |
Ejemplares similares
-
Drugs for paediatric hyperinflammatory syndromes
por: Hon, Kam Lun, et al.
Publicado: (2022) -
Colchicine and SARS-CoV-2: Management of the hyperinflammatory state
por: Vitiello, Antonio, et al.
Publicado: (2021) -
Can beta-adrenergic blockers be used in the treatment of COVID-19?
por: Vasanthakumar, Natesan
Publicado: (2020) -
Beta-Adrenergic Agonists
por: Barisione, Giovanni, et al.
Publicado: (2010) -
Haemophagocytic lymphohisticytosis—an underrecognized hyperinflammatory syndrome
por: Hutchinson, Matthew, et al.
Publicado: (2019)